Postoperative PainNCT03769818
Role of Dexamethasone for Erector Spinae Plane Block in Patients Undergoing Total Abdominal Hysterectomy
A study testing bupivacaine and dexamethasone in people with Postoperative Pain, run by Aswan University Hospital at 1 site in Egypt.
Trial summary
The aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone for erector spinae plane block for postoperative analgesia in patients undergoing total abdominal hysterectomy Group 1: bupivacaine 0.25% + dexamethasone 8 mg Group 2: bupivacaine 0.25% Group3: control group A… Read more about this study
- Who is it for?
- Ages 30 to 60 years, women only
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- bupivacaine and dexamethasone
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2019to 1 Aug 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women ranging age between 30-60 years a who undergoing elective total abdominal hysterectomy
Who cannot join
- Participants had known sensitivity to bupivacaine
- Participants had difficulty in intubation
- Participants were on chronic pain medication or already on long-term opioids
- Participants smokers
- Participants with disabilities who were unable to communicate pain levels
- refuse to consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Role of Adjuvant Dexamethasone for Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Total Abdominal Hysterectomy: A Randomized, Double-blind Controlled Trial
The aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone for erector spinae plane block for postoperative analgesia in patients undergoing total abdominal hysterectomy Group 1: bupivacaine 0.25% + dexamethasone 8 mg
- Group 2: bupivacaine 0.25%
- Group3: control group A prospective Randomized Interventional double-blind study.
Read the detailed description
Optimal dynamic analgesia is recognized as the key to enhanced recovery following open abdominal surgery. In the last decade, there has been a significant shift away from thoracic epidural analgesia (TEA) that has been long considered as the gold standard. Various techniques have tried to replicate the analgesic efficacy of TEA. They include transversus abdominis plane analgesia (TAP), rectus sheath analgesia (RS), wound infusion analgesia (WI) and trans muscular quadratus lumborum analgesia. However, each of these techniques has specific limitations that prevent them from being the analgesic technique of choice for all open abdominal surgeries. Chin et al first described the erector spinae plane (ESP) block for providing analgesia following ventral hernia repair. The unique feature of the ultrasound-guided truncal blocks is that in all of these techniques, in contrast to peripheral nerve blocks, no nerve or plexus needs to be identified: Local anesthesia (LA) is injected in a particular muscle plane, in which the injectate spreads and reaches the intended nerves. This simple mechanism has made delivery of nerve blocks easy and versatile.
- Conditions
- Postoperative Pain
- Being tested
- bupivacaine, dexamethasone, placebo to dexamethasone, placebo to bupivacaine
- Keywords
- erector spinae plane block, total abdominal hysterectomy, dexamethasone
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bupivacaineDrug
Also called Active Comparator
Bilateral TAP block with 20 ml of 0.25% bupivacaine
dexamethasoneDrug
Also called active comparator
Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
placebo to dexamethasoneDrug
Bilateral TAP block with placebo to dexamethasone.
placebo to bupivacaineDrug
Bilateral TAP block with placebo to bupivacaine.
| Study group | Role | What they receive |
|---|---|---|
| bupivacaine and dexamethasone | Active comparator | Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline. Receives: Drug: bupivacaine; Drug: dexamethasone |
| bupivacaine and placebo to dexamethasone | Active comparator | Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone Receives: Drug: bupivacaine; Drug: placebo to dexamethasone |
| control group | Placebo comparator | Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone Receives: Drug: placebo to dexamethasone; Drug: placebo to bupivacaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual analog score for pain during movement
movement-evoked pain measurements ranging from 0 to 10, where 0 no pain and 10 maximum pain
Measured: 24 hours post operative
Secondary outcomes (3)
Visual analog score for pain during rest
ranging from 0 to 10, where 0 no pain and 10 maximum pain
Measured: 24 hours postoperative
number of patients need Fentanyl consumption
calculation of the number of patients need Fentanyl consumption
Measured: 24 hours postoperative
number of days patients stay in hospital
calculation of number of days patients stay in hospital
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2018
- Study start1 Jan 2019
- Primary completion30 Mar 2020
- Study completion1 Aug 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A prospective Randomized Interventional double-blind study.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aswan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, hany farouk, Aswan University Hospital
- Investigators
- hany f sallam, md, Principal investigator, Aswan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03769818
- Sponsor's protocol ID
- aswu/181/18
- Status last verified
- Aug 2020
- First submitted
- 6 Dec 2018
- Last updated
- 5 Aug 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Adjuvant Dexamethasone for Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Total Abdominal Hysterectomy: A Randomized, Double-blind Controlled Trial
- ClinicalTrials.gov ID
- NCT03769818
- Acronym / sponsor ID
- aswu/181/18
- Conditions
- Postoperative Pain
- Keywords
- erector spinae plane block, total abdominal hysterectomy, dexamethasone
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Aswan University HospitalUniversity, hospital or other
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- 30 Mar 2020 (actual)
- Study completion
- 1 Aug 2020 (actual)
- First posted
- 10 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone for erector spinae plane block for postoperative analgesia in patients undergoing total abdominal hysterectomy Group 1: bupivacaine 0.25% + dexamethasone 8 mg
- Group 2: bupivacaine 0.25%
- Group3: control group A prospective Randomized Interventional double-blind study.
Detailed description
Optimal dynamic analgesia is recognized as the key to enhanced recovery following open abdominal surgery. In the last decade, there has been a significant shift away from thoracic epidural analgesia (TEA) that has been long considered as the gold standard. Various techniques have tried to replicate the analgesic efficacy of TEA. They include transversus abdominis plane analgesia (TAP), rectus sheath analgesia (RS), wound infusion analgesia (WI) and trans muscular quadratus lumborum analgesia. However, each of these techniques has specific limitations that prevent them from being the analgesic technique of choice for all open abdominal surgeries. Chin et al first described the erector spinae plane (ESP) block for providing analgesia following ventral hernia repair. The unique feature of the ultrasound-guided truncal blocks is that in all of these techniques, in contrast to peripheral nerve blocks, no nerve or plexus needs to be identified: Local anesthesia (LA) is injected in a particular muscle plane, in which the injectate spreads and reaches the intended nerves. This simple mechanism has made delivery of nerve blocks easy and versatile.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- A prospective Randomized Interventional double-blind study.
| Arm | Type | Receives |
|---|---|---|
| bupivacaine and dexamethasone | Active comparator | Drug: bupivacaine, Drug: dexamethasoneBilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline. |
| bupivacaine and placebo to dexamethasone | Active comparator | Drug: bupivacaine, Drug: placebo to dexamethasoneBilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone |
| control group | Placebo comparator | Drug: placebo to dexamethasone, Drug: placebo to bupivacaineBilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Women ranging age between 30-60 years a who undergoing elective total abdominal hysterectomy
Key exclusion criteria (6 listed)
- Participants had known sensitivity to bupivacaine
- Participants had difficulty in intubation
- Participants were on chronic pain medication or already on long-term opioids
- Participants smokers
- Participants with disabilities who were unable to communicate pain levels
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bupivacaineAlso: Active ComparatorBilateral TAP block with 20 ml of 0.25% bupivacaine | Drug | bupivacaine and dexamethasone, bupivacaine and placebo to dexamethasone |
| dexamethasoneAlso: active comparatorBilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline. | Drug | bupivacaine and dexamethasone |
| placebo to dexamethasoneBilateral TAP block with placebo to dexamethasone. | Drug | bupivacaine and placebo to dexamethasone, control group |
| placebo to bupivacaineBilateral TAP block with placebo to bupivacaine. | Drug | control group |
Primary outcome
Visual analog score for pain during movement
Time frame: 24 hours post operative
movement-evoked pain measurements ranging from 0 to 10, where 0 no pain and 10 maximum pain
3 secondary outcomes
Visual analog score for pain during rest
Time frame: 24 hours postoperative
number of patients need Fentanyl consumption
Time frame: 24 hours postoperative
number of days patients stay in hospital
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2020.
- Individual participant dataSharing planned: Undecided
Related trials for Postoperative Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
hany f sallam, md principal investigator
Aswan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing bupivacaine and dexamethasone in people with Postoperative Pain, run by Aswan University Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual analog score for pain during movement (time frame: 24 hours post operative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2020.